Affiliation:
1. Dagestan State Medical University
Abstract
The study included 1124 hospitalized patients with COVID-19, who were divided into 2 groups: those who received antifungal agents (main); not receiving them (control). Within the groups, 2 subgroups were distinguished depending on the outcome of treatment: survivors and deceased. According to our results, triazoles (56.6%) and polyenes (46.6%) were used most frequently for the treatment of concomitant fungal diseases. A great influence on the lethality of patients with COVID-19 was exerted by the elderly age of the patient and the presence of complications in the form of respiratory failure, regardless of the use of antifungal agents.
Reference29 articles.
1. Zhou P., Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270-3. 10.1038/s41586-020-2012-7.
2. Munster VJ., Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med. (2020) 382:692-4. 10.1056/NEJMp2000929.
3. Template:COVID-19_pandemic_data https://en.wikipedia.org/wiki (дата обращения 29.01.2022).
4. Canning B., Senanayake R.V., Burns D., Moran E., Dedicoat M. Post-influenza aspergillus ventriculitis. Clin Infect Pract. 2020:100026. doi: 10.1016/j.clinpr.2020.100026.
5. Ripa M., Galli L., Poli A., Oltolini C., Spagnuolo V., Mastrangelo A., Muccini C., Monti G., De Luca G., Landoni G., et al. Secondary infections in patients hospitalized with COVID-19: Incidence and predictive factors. Clin. Microbiol. Infect. 2021;27:451-457. doi: 10.1016/j.cmi.2020.10.021.